Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Richard Barry Parad, M.D.

TitleAssociate Professor of Pediatrics
InstitutionBrigham and Women's Hospital
DepartmentPediatrics
AddressBrigham and Women's Hospital
Newborn Medicine, CWN-418
75 Francis St
Boston MA 02115
Phone617/732-7371
Fax617/278-6983

 Mentoring 
 completed student projects
The Expression of Bacterial Permeability - Increasing Proteina nd Monocyte/Neutrophil Elastase Inhibitor in Newborns of Different Gestational Ages
Summer, 06/21/99 - 08/20/99
Study of Innate Defense in Critically Ill Premature Neonates: Measurement of Bactericidal/Permeability - Increasing Protein in the Tracheal Aspirate Derived Neutrophils
Part Time/Continuation, 09/01/00 - 02/28/01
Study of Innate Defense In Critically Ill Premature Neonates: Measurementof Bactericidal/Permeability Increasing Protein in the New Tracheal Aspirate-derived Neutrophils
Summer/Continuation, 06/17/00 - 08/31/00
Study of Innate Defense in Critically Il Premature Neonates
Part Time, 02/01/00 - 06/16/00

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Nathe KE, Mancuso CJ, Parad R, Van Marter LJ, Martin CR, Stoler-Barak L, Philbin VJ, Phillips MF, Palmer CD, Levy O. Innate immune activation in neonatal tracheal aspirates suggests endotoxin-driven inflammation. Pediatr Res. 2012 Aug; 72(2):203-11.
    View in: PubMed
  2. Parad RB, Allred EN, Rosenfeld WN, Davis JM. Reduction of retinopathy of prematurity in extremely low gestational age newborns treated with recombinant human Cu/Zn superoxide dismutase. Neonatology. 2012; 102(2):139-44.
    View in: PubMed
  3. Parad RB. Update on the diagnosis and management of bronchopulmonary dysplasia/chronic lung disease of infancy: what the radiologist should know. Pediatr Radiol. 2012 Jan; 42 Suppl 1:S92-100.
    View in: PubMed
  4. Als H, Duffy FH, McAnulty G, Butler SC, Lightbody L, Kosta S, Weisenfeld NI, Robertson R, Parad RB, Ringer SA, Blickman JG, Zurakowski D, Warfield SK. NIDCAP improves brain function and structure in preterm infants with severe intrauterine growth restriction. J Perinatol. 2012 Oct; 32(10):797-803.
    View in: PubMed
  5. Keiles S, Koepke R, Parad R, Kharrazi M. Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening. J Cyst Fibros. 2012 May; 11(3):257-60.
    View in: PubMed
  6. Nguyen RH, Umbach DM, Parad RB, Stroehla B, Rogan WJ, Estroff JA. US assessment of estrogen-responsive organ growth among healthy term infants: piloting methods for assessing estrogenic activity. Pediatr Radiol. 2011 May; 41(5):633-42.
    View in: PubMed
  7. Labrecque M, Parad RB, Gupta M and Hansen A. Donation after Cardiac Death: The Potential Contribution of an Infant Organ Donor Population. J Pediatr. 2010; in press..
  8. Glotzbecker MP, Estroff JA, Spencer SA, Bosley JC, Parad RB, Kasser JR, Mahan ST. Prenatally diagnosed clubfeet: comparing ultrasonographic severity with objective clinical outcomes. J Pediatr Orthop. 2010 Sep; 30(6):606-11.
    View in: PubMed
  9. Labrecque M, Parad R, Gupta M, Hansen A. Donation after cardiac death: the potential contribution of an infant organ donor population. J Pediatr. 2011 Jan; 158(1):31-6.
    View in: PubMed
  10. Als H, Duffy FH, McAnulty GB, Fischer CB, Kosta S, Butler SC, Parad RB, Blickman JG, Zurakowski D, Ringer SA. Is the Newborn Individualized Developmental Care and Assessment Program (NIDCAP) effective for preterm infants with intrauterine growth restriction? J Perinatol. 2011 Feb; 31(2):130-6.
    View in: PubMed
  11. Parad RB. HFOV in preterms: an individual patients' data meta-analysis. Lancet. 2010 Jun 12; 375(9731):2054-5.
    View in: PubMed
  12. Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O'Sullivan BP, Spencer T, Yee W, Comeau AM. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis. 2010 Oct; 33(Suppl 2):S255-61.
    View in: PubMed
  13. Als H, Duffy, FH, McAnulty G, Fischer CB, Kosta S, Butler SC, Parad RB, Blickman JG, Zurakowski D, Ringer SA. Is the Newborn Individualized Developmental Care and Assessment Program (NIDCAP) Effective for Preterm Infants with Intrauterine Growth Restriction?. Journal of Perinatology. 2010; In press.
  14. Glotzbecker M, Estroff JA, Spencer S, Bosley JC, Parad RB, Kasser JR, Mahan ST. Prenatally diagnosed clubfeet: Comparing ultrasonographic severity with objective clinical outcomes. Journal of Pediatric Orthopaedics. 2010; in press.
  15. Marchione, Marilynn . AP IMPACT: Testing curbs some genetic diseases (Associated Press interview by Marilynn Marchione): http://www.npr.org/templates/story/story.php?storyId=123798798 http://abcnews.go.com/Technology/wireStory?id=9877649 http://news.yahoo.com/s/ap/20100218/ap_on_sc/us_med_gene_testing http://www.washingtonpost.com/wp-dyn/content/article/2010/02/21/AR2010022101704.html http://www.foxnews.com/story/0,2933,586331,00.html,http://www.cnbc.com/id/35369312/ http://www.nytimes.com/aponline/2010/02/18/science/AP-US-MED-Gene-Testing.html?ref=aponline. 2010.
  16. Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, Sontag MK, Rosenfeld M, Davis SD, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr. 2009 Dec; 155(6 Suppl):S106-16.
    View in: PubMed
  17. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009 Dec; 155(6 Suppl):S73-93.
    View in: PubMed
  18. Borowitz D, Parad RB, Sharp JS, Sabadosa KA, Robinson KA, Rock MJ, Farrell PN, Sontag MK, Rosenfeld M, Davis SD, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation Practice Guidelines for the Management of Infants with Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome during the First Two Years of Life and Beyond . J Peds. 2009; 155(6, Supplement 1):S71-S116 .
  19. Borowitz B, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL Michel SH, Parad RP, White T, Farrell PM, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. J Peds. 2009; 155(6, Supplement 1):S71-S116.
  20. McAnulty G, Duffy FH, Butler S, Parad R, Ringer S, Zurakowski D, Als H. Individualized developmental care for a large sample of very preterm infants: health, neurobehaviour and neurophysiology. Acta Paediatr. 2009 Dec; 98(12):1920-6.
    View in: PubMed
  21. Steven Keile, Ruth Koepke, Richard Parad, Martin Kharrazi, California CF Newborn Screening Consortium. Impact of IVS8-(TG)m(T)n Haplootype on Immunorreactive Trypsinogen (IRT) and Sweat Chloride (SC) Levels in a Cohort of Hypertrypsinogenemic (HT) Newborns with Genotype DF508/5T Identified by the California (CA) Cystic Fibrosis (CF) Newborn Screen (NBS) . Ped Pulmonol. 2009.
  22. Nathe KE, Parad R, Van Marter LJ, Lund CA, Suter EE, Hernandez-diaz S, Boush EB, Ikonomu E, Gallington L, Morey JA, Zeman AM, Mcnamara M, Levy O. Endotoxin-directed innate immunity in tracheal aspirates of mechanically ventilated human neonates. Pediatr Res. 2009 Aug; 66(2):191-6.
    View in: PubMed
  23. Nathe K, Stoler-Barak L, Philbin V, Parad R, Van Marter L, Levy O . Early Activation of an Innate Immune Transcriptome and Identification of Calgranulin C Expression. Ped Research. 2009.
  24. Levesque B, Hernandez-Diaz S, Parad R, Phillips M, Gupta M, Ingber D, Van Marter L . BPD: Clinical Results Title: Urinary Vascular Endothelial Growth Factor (VEGF): Correlation with Mechanical Ventilation and Bronchopulmonary Dysplasia (BPD) in Infants Born before 29 Weeks Gestation. Ped Research. 2009.
  25. Welty S, Lynch S, O’Shea TM, Malcolm W, Kallapur S, Auten R, Martin R,Truog W, Nelin L, Nogee L, Parad RB, Abman S, Bancalari E, Walsh M. 2009 BPD Roundtable: http://www.nationwidechildrens.org/bpd-roundtable. 2009.
  26. Carlson D, McKeen E, Mitchell M, Torres B, Parad R, Comeau AM, O'Sullivan BP. Oropharyngeal flora in healthy infants: observations and implications for cystic fibrosis care. Pediatr Pulmonol. 2009 May; 44(5):497-502.
    View in: PubMed
  27. Parad R, Davis J, Marlow N, Peacock J, Calvert S, Greenough A . A Chronic Respiratory Morbidity (CRM) Definition Derived from 12 Month (M) Respiratory Symptom Diaries (RD) Predicts 12m Pulmonary Function (PFT) and 24m Respiratory Health in Extremely Low Gestational Age Newborns (ELGANs). Ped Research. 2009.
  28. Michael P Glotzbecker MD, Judy A Estroff MD, Susan T Mahan MD, MPH, Justin C Bosley, Richard B Parad MD MPH, Samantha A Spencer, MD, James R Kasser MD . Prenatally Diagnosed Clubfeet: Comparing Ultrasonographic Severity with Clinical Outcomes. http://posna.gmetonline.com/ViewPresentation.aspx?subscriptionpackageid=31. 2009.
  29. McBride JA, Parad RB, Davis JM, Zheng Z, Zupancic JA. Economic evaluation of recombinant human copper zinc superoxide dismutase administered at birth to premature infants. J Perinatol. 2009 May; 29(5):364-71.
    View in: PubMed
  30. Davis J, Parad R. The Use of Antioxidants to Prevent or Ameliorate Bronchopulmonary Dysplasia (Chapter 26). Abman S, ed. Bronchopulmnary Dysplasia (Lung Biology in Health and Disease Vol 240, Lenfant C ed.). 2009; 458-471.
  31. Baby's first test: Newborn Screening. 2008.
  32. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008 Aug; 153(2):S4-S14.
    View in: PubMed
  33. Hale JE, Parad RB, Comeau AM. Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med. 2008 Feb 28; 358(9):973-4.
    View in: PubMed
  34. Parad R. Bronchopulmonary Dysplasia. Manual of Neonatal Care (Cloherty JP, Eichenwald, EC, Stark AR, editors). 2007.
  35. Green R. Summary of Workgroup Meeting on Use of Family History Information in Pediatric Primary Care and Public Health. Pediatrics. 2007; 120(Supplement 2):S87-S100.
  36. Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O'Sullivan BP. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics. 2007 Feb; 119(2):e495-518.
    View in: PubMed
  37. Nathe K, Suter E, Lund C, Parad R, Morey J, Van Marter L, Levy O. Endotoxin-directed innate immunity in tracheal aspirates of critically ill premature human neonates: Mobilization of bactericidal permeability increasing protein (BPI), LPS-Binding Protein, and Soluble CD14. Pediatric Research. 2007.
  38. Parad R, Allred E, Rosenfeld W, Davis J. Incidence and Severity of Retinopathy of Prematurity (ROP) is Reduced in Extremely Low Gestational Age (GA) Newborns (ELGANS) Treated with Recombinant Human Cu/Zn Superoxide Dismutase (rhSOD). Pediatric Research. 2007; E-PAS2007:618225.6.
  39. O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R. Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics. 2006 Sep; 118(3):1260-5.
    View in: PubMed
  40. Estroff J, Parad R, Stroehla B, Umbach D and Rogan W. Developing Methods for Studying Estrogen-like Effects of Soy Isoflavones in Infants 3: Ultrasound . PAS. 2006.
  41. Van Marter L, Allred E, Morey J, Parad R, Vitali S, Kourembanas S. Bilirubin and Bronchopulmonary Dysplasia Among Extremely Low Gestational Age Newborns. PAS. 2006.
  42. Parad R. Family History and Single Gene Disorders: Cystic Fibrosis. Use of Family History Information in Pediatric Primary Care and Public Health, a Workgroup at Centers for Disease Control and Prevention National Center on Birth Defects and Developmental Disabilities. 2006; http://www.cdc.gov/ncbddd/bd/f.
  43. Parad R, Allred E, Davis J . Incidence And Severity of Retinopathy of Prematurity (Rop) is Reduced in Extremely Low Gestational Age (GA) Newborns (ELGANs) Treated with Recombinant Human Cu/Zn Superoxide Dismutase (rhSOD). Journal of European Pediatrics. 2006.
  44. Estroff J, Wong J, Parad R, Tanden R, Barnewolt C,. Accuracy of Prenatal Imaging of Fetal Cleft Palate by MRI. Presented at IFMSS, Kona, Hawaii. 2006.
  45. Lang J E, Forbes P J, Parchesky A, Little M, Hale J, Parad R, Comeau A, Waltz D A. Safety, Feasibility, and Quality Assurance of Sweat Testing in Newborn Infants. Pediatric Pulmonology. 2006.
  46. Parad, R and Ren, C. Role of the CF Clinician in the Implementation and Maintenance of CF Newborn Screening Programs. 2005.
  47. Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr. 2005 Sep; 147(3 Suppl):S98-100.
    View in: PubMed
  48. Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr. 2005 Sep; 147(3 Suppl):S89-93.
    View in: PubMed
  49. Wilfond BS, Parad RB, Fost N. Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr. 2005 Sep; 147(3 Suppl):S109-13.
    View in: PubMed
  50. Parad RB, Comeau AM, Dorkin HL, Dovey M, Gerstle R, Martin T, O'Sullivan BP. Sweat testing infants detected by cystic fibrosis newborn screening. J Pediatr. 2005 Sep; 147(3 Suppl):S69-72.
    View in: PubMed
  51. Parad RB, Comeau AM. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J Pediatr. 2005 Sep; 147(3 Suppl):S78-82.
    View in: PubMed
  52. Parad R, Comeau A, Soultan Z, Anbar R, Pass K, Caggana M, Dorkin H, Quizon A, Waltz D, Martin M, Schechter M, Borowitz D, Voter K, Ren C, Dozor A, Kaslovsky R, Comber P, O’Sullivan B . Outcomes of a Cohort of Immunoreactive Trypsinogen (IRT)/DNA Cystic Fibrosis Newborn Screening (CFNBS) Positive Infants with R117H as One of Two Detected CFTR Mutations: Worrisome Throat Culture Findings. Pediatr Pulmonology. 2005; S28:256.
  53. Parad, R, Farrell, P, Campbell, P. Newborn Screening for Cystic Fibrosis: Evaluation of Benefits and Risks and Recommendations for State Newborn Screening Programs. J Pediatr 147(3):. 2005; 147(3 (Supplement 1)):S1-S114 .
  54. Parad RB, Comeau AM, Hale J. Removal of CFTR mutation R117H from the cystic fibrosis (CF) newborn screening (NBS) mutation panel would decrease detection of atypical CF. Pediatric Academic Societies Meeting. PAS. 2005; 57:2311.
  55. McBride J, Parad R, Davis J, Allred L, Zupancic J. Cost analysis on the use of recombinant human superoxide dismutase (rhSOD) at birth in preterm infants to improve pulmonary outcome. PAS. 2005; 57:1232.
  56. Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004 Jun; 113(6):1573-81.
    View in: PubMed
  57. Parad RB, Comeau AM, Dovey M, Martin T, Dorkin H, O’Sullivan B, Gerstle R. Prevalence of immunoreactive trypsinogen (IRT) level below newborn screen cutoff in CF that presents with meconium ileus. Eighteenth Annual North American Cystic Fibrosis Conference, St. Louis, MO. Ped Pulm. 2004; S27:226.
  58. Parad RB, Estrella E, Comeau AM, Hawley P. Attitute toward CF newborn screening after receiving false positive results: Impact of genetic counseling on parents identified as carriers. Eighteenth Annual North American Cystic Fibrosis Conference, St. Louis, MO. Pediatr Pulmonol. 2004; S27:226-227.
  59. Ward VL, Barnewolt CE, Estroff JA, Levine D, Mehta TS, Parad RB. Work-in-Progress for the SPR Millennium Grant: Fetal MR of Chest Masses. The Society for Pediatric Radiology. 2004.
  60. Als H, Gilkerson L, Duffy FH, McAnulty GB, Buehler DM, Vandenberg K, Sweet N, Sell E, Parad RB, Ringer SA, Butler SC, Blickman JG, Jones KJ. A three-center, randomized, controlled trial of individualized developmental care for very low birth weight preterm infants: medical, neurodevelopmental, parenting, and caregiving effects. J Dev Behav Pediatr. 2003 Dec; 24(6):399-408.
    View in: PubMed
  61. Parad RB, Comeau AM. Newborn screening for cystic fibrosis. Pediatr Ann. 2003 Aug; 32(8):528-35.
    View in: PubMed
  62. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics. 2003 Mar; 111(3):469-76.
    View in: PubMed
  63. Ward VL, Barnewolt CE, Estroff JA, Levine D, Mehta TS, Parad RB. Work-in-Progress for the SPR Millennium Grant: Fetal MR of Chest Masses. Pediatric Radiology. 2003.
  64. Parad RB and Comeau AM. Cystic Fibrosis Newborn Screening. Pediatric Annals. 2003; 32(8):528-35.
  65. Ward VL, Barnewolt CE, Estroff JA, Levine D, Mehta TS, Parad RB. Work-in-Progress for the SPR Millennium Grant: Fetal MR of Chest Masses. The Society for Pediatric Radiology. 2003.
  66. Parad RB, Comeau A, Dorkin H, Dovey M, Martin T, Gerstle R, O’Sullivan B. Outcome after an initial borderline sweat test in hypertrypsinogenemic infants detected through CF newborn screening. Pediatric Pulmonology. 2003; sup: 222-223.
  67. Parad R. Bronchopulmonary Dysplasia (Chronic Lung Disease). Manual of Neonatal Care (Cloherty JP, Eichenwald, EC, Stark AR, editors). 2003.
  68. Comeau A, Parad RB, Dorkin H, Dovey M, Haver K, Lapey A, Gerstle R, O’Sullivan B. Increased sensitivity at the cost of increased referrals when population-based newborn screening incorporates testing for multiple allele mutations (MM): Cystic Fibrosis (CF) newborn screening (NBS) as a model. Am J Hum Genet. 2003; (73):( 5 sup ): 213.
  69. Cullen A, Van Marter LJ, Allred EN, Moore M, Parad RB, Sunday ME. Urine bombesin-like peptide elevation precedes clinical evidence of bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2002 Apr 15; 165(8):1093-7.
    View in: PubMed
  70. Parad, R. An Unexpected Screening Result© (IN703.3). 2002.
  71. Davis JM, Parad R. The role of oxidant injury in the pathogenesis of bronchopulmonary dysplasia. Basic Mechanisms of Pediatric Respiratory Disease (Haddad GG, Abman SH, Chernick V, editors). 2002; 505-517.
  72. Wheeler PG, Smith R, Dorkin H, Parad RB, Comeau AM, Bianchi DW. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: Two years' experience in one medical center. Genet Med. 2001 Nov-Dec; 3(6):411-5.
    View in: PubMed
  73. Van Marter LJ, Allred EN, Leviton A, Pagano M, Parad R, Moore M. Antenatal glucocorticoid treatment does not reduce chronic lung disease among surviving preterm infants. J Pediatr. 2001 Feb; 138(2):198-204.
    View in: PubMed
  74. Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M, Susser M, Paneth N, Leviton A. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics. 2000 Jun; 105(6):1194-201.
    View in: PubMed
  75. Davis JM, Richter SE, Biswas S, Rosenfeld WN, Parton L, Gewolb IH, Parad R, Carlo W, Couser RJ, Baumgart S, Atluru V, Salerno L, Kassem N. Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase. J Perinatol. 2000 Jun; 20(4):213-6.
    View in: PubMed
  76. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun. 1999 Sep; 67(9):4744-50.
    View in: PubMed
  77. Chiba-Falek O, Parad RB, Kerem E, Kerem B. Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation. Am J Respir Crit Care Med. 1999 Jun; 159(6):1998-2002.
    View in: PubMed
  78. Parad RB. Developing fetal diagnostic techniques. Prenatal Care (McCormick MC, Siegel JE, editors). 1999; 231-243.
  79. Parad RB. Buccal cell DNA mutation analysis for diagnosis of cystic fibrosis in newborns and infants inaccessible to sweat chloride measurement. Pediatrics. 1998 May; 101(5):851-5.
    View in: PubMed
  80. Parad R, Berger T. Chronic Lung Disease. Manual of Neonatal Care (Cloherty JP, Stark AR, editors). 1997; 378-388.
  81. Davis JM, Rosenfeld W, Richter SE, Parad RB, Gewolb IH, Spitzer A, Carlo W, Couser R, Price A, Flaster E, Kassem N, Edwards L, Tierney J, Horowitz S. . Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics. 1997; 100:24-30.
  82. Parad RB. Heterogeneity of phenotype in two cystic fibrosis patients homozygous for the CFTR exon 11 mutation G551D. J Med Genet. 1996 Aug; 33(8):711-3.
    View in: PubMed
  83. Bromley B, Parad R, Estroff JA, Benacerraf BR. Fetal lung masses: prenatal course and outcome. J Ultrasound Med. 1995 Dec; 14(12):927-36; quiz p1378.
    View in: PubMed
  84. Estroff JA, Parad RB, Barnes PD, Madsen JP, Benacerraf BR. Posterior fossa arachnoid cyst: an in utero mimicker of Dandy-Walker malformation. J Ultrasound Med. 1995 Oct; 14(10):787-90.
    View in: PubMed
  85. Parad RB, Applegate K, Doubilet PM, Fishman SJ, Estroff JA. Occult fetal bowel obstruction: ileal atresia presenting in a newborn infant after normal antenatal sonography. J Ultrasound Med. 1995 Feb; 14(2):161-3.
    View in: PubMed
  86. Parad RB . Applications of genetic information regarding the gene responsible for cystic fibrosis (Part 2). The International Association of Cystic Fibrosis Adults Newsletter. 1995; (41):3-9.
  87. Estroff JA, Parad RB, Share JC, Benacerraf BR. Second trimester prenatal findings in duodenal and esophageal atresia without tracheoesophageal fistula. J Ultrasound Med. 1994 May; 13(5):375-9.
    View in: PubMed
  88. Parad RB. Applications of genetic information regarding the gene responsible for cystic fibrosis (Part 1). The International Association of Cystic Fibrosis Adults Newsletter. 1994; (40):3-8.
  89. The Cystic Fibrosis Genetic Analysis Consortium, Population variation of common cystic fibrosis mutations. Hum Mutat. 1994; 4:167-77.
  90. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, Parad RB, Witt D, Klinger KW. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993 Feb; 2(2):159-63.
    View in: PubMed
  91. Estroff JA, Parad RB, Teele RL, Benacerraf BR. Echogenic vessels in the fetal thalami and basal ganglia associated with cytomegalovirus infection. J Ultrasound Med. 1992 Dec; 11(12):686-8.
    View in: PubMed
  92. Davis AE, Aulak K, Parad RB, Stecklein HP, Eldering E, Hack CE, Kramer J, Strunk RC, Bissler J, Rosen FS. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nat Genet. 1992 Aug; 1(5):354-8.
    View in: PubMed
  93. Estroff JA, Parad RB, Benacerraf BR. Prevalence of cystic fibrosis in fetuses with dilated bowel. Radiology. 1992 Jun; 183(3):677-80.
    View in: PubMed
  94. Bromley B, Estroff JA, Sanders SP, Parad R, Roberts D, Frigoletto FD, Benacerraf BR. Fetal echocardiography: accuracy and limitations in a population at high and low risk for heart defects. Am J Obstet Gynecol. 1992 May; 166(5):1473-81.
    View in: PubMed
  95. Estoff JA, Parad RB, Frigoletto FD, Benacerraf BR. The natural history of isolated fetal hydrothorax. Ultrasound Obstet Gynecol. 1992 May 1; 2(3):162-5.
    View in: PubMed
  96. Parad RB. Ontogeny of nonimmune defense mechanisms. Semin Perinatol. 1992 Apr; 16(2):97-105.
    View in: PubMed
  97. Parad RB, Gerard C. A sequence variation in intron 17B of the cystic fibrosis transmembrane conductance regulator gene. Hum Mutat. 1992; 1(3):258-9.
    View in: PubMed
  98. Davis E, III, Aulak K, Parad RB, Stecklein HP, Eldering E, Hack CE, Kramer J, Strunk RC, Bissler J, Rosen FS. . C1 Inhibitor hinge region mutations may convert the inhibitor to a substrate or may result in the inability to interact with target proteases. Nat Genet. 1992; 1:354-58.
  99. Parad, R, Ringer, S. Neonatology Core Curriculum, Volume III (2008 edition). 1991.
  100. Parad, R, Ringer, S. Neonatology Core Curriculum, Volume II (2008 edition). 1991.
  101. Parad R. Chronic Lung Disease (formerly Bronchopulmonary Dysplasia). Manual of Neonatal Care (Cloherty JP, Stark AR, editors). 1991; 237-246.
  102. Johnson, L, Keefer, C, Parad, R and O'Brien, S. Neonatology Core Curriculum, Volume I (2005 edition). 1991.
  103. Parad RB, Kramer J, Strunk RC, Rosen FS, Davis AE. Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc Natl Acad Sci U S A. 1990 Sep; 87(17):6786-90.
    View in: PubMed
  104. Parad RB, Wohl MEB. . Bronchopulmonary dysplasia. Curr Opin Pediatr. 1990; (2):459-464.
  105. O'Rourke PP, Crone RK, Vacanti JP, Ware JH, Lillehei CW, Parad RB, Epstein MF. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study. Pediatrics. 1989 Dec; 84(6):957-63.
    View in: PubMed
  106. Ariga T, Igarashi T, Ramesh N, Parad R, Cicardi M, Davis AE. Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. J Clin Invest. 1989 Jun; 83(6):1888-93.
    View in: PubMed
  107. Gitlin JD, Soll RF, Parad RB, Horbar JD, Feldman HA, Lucey JF, Taeusch HW. Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics. 1987 Jan; 79(1):31-7.
    View in: PubMed
  108. Fox R, Parad R, Demling R, Merrigan M. Increased permeability of isolated rat lungs perfused with an oxygen radical generator (purine-xanthine oxidase) under constant pressure conditions. Physiology of Oxygen Radicals (Taylor A, editor). 1986.
  109. Gitlin JD, Parad R, Taeusch HW. Exogenous surfactant therapy in hyaline membrane disease. Semin Perinatol. 1984 Oct; 8(4):272-82.
    View in: PubMed
  110. Richard B. Parad. Marihuana and the Lungs: Combined Effects of Marihuana and Alcohol on Pulmonary Host Defense Mechanisms. (Thesis approved for Honors in Biology). 1977.
  111. Parad R, Simmons G, Feldman N, Huber G. Impairment of adaptive tolerance to oxygen toxicity by systemic immunosuppression. Chest. 1975 Feb; 67(2 Suppl):42S-43S.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Parad's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (303) concept(s)
_
Co-Authors
See all (41) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_